Knowledge graph · Drug
Selumetinib
small molecule
- Identifier
- CI-DRUG-00000548
- Entity page
- /drug/selumetinib ↗
- Edges
- 335
- Neighbours
- 52 cancers2 genes12 variants10 trials10 approvals
- Drawn
- 60 of 86 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Selumetinib approved for …APPROVED_FORderived10 of 10 | ||||||||
| → approved for | FDA · US · 2025Efficacy supplement 2025-11-19 (see label) FDA (US) · approved · 2025-11-19 · Efficacy supplement 2025-11-19 (see label) | — | approved | not mapped | 1 | Regulatory | openfda | open ↗ |
| → approved for | FDA · US · 2025KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) [see Dosage and Administration (2) ]. KOSELUGO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). ( 1 ) | |||||||